HYPERTROPHIC CARDIOMYOPATHY IN MULTIMORBIDITY

  • A. I. Lakhonina V.N. Karazin Kharkiv National University, Kharkiv, Ukraine https://orcid.org/0000-0001-7188-6468
  • A. V. Filatova V.N. Karazin Kharkiv National University, Kharkiv, Ukraine
  • N. V. Makienko V.N. Karazin Kharkiv National University, Kharkiv, Ukraine
  • N. A. Vodyanitska V.N. Karazin Kharkiv National University, Kharkiv, Ukraine
Keywords: hypertrophic cardiomyopathy, multimorbidity, diagnosis, rational pharmacotherapy, quality of life, disease prevention

Abstract

Aspects of diagnosis, difficulties in the diagnosis and optimal therapeutic strategies in patient with hypertrophic cardiomyopathy and comorbid conditions such as arterial hypertension, ischemic heart disease, dyslipidemia, diabetes mellitus type 2, stenosis of the left renal artery, obesity are reviewed on the example of clinical case. Hypertrophic cardiomyopathy combined with multimorbidity conditions requires a high-quality medical management, where the main goal is to improve the quality and duration of patient's life. This goal is being achieved by optimizing patient's lifestyle and assigning only the minimum amount of medications. Necessity of careful diagnosis of hypertrophic cardiomyopathy, evaluation of the risk of sudden death and search of optimal treatment in patients with multimorbidity pathology are demonstrated in clinical case.

Downloads

Download data is not yet available.

Author Biographies

A. I. Lakhonina, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine

Svobody sq., 6, Kharkiv, 61022, Ukraine

 
A. V. Filatova, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine

Svobody sq., 6, Kharkiv, 61022, Ukraine

 
N. V. Makienko, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine

Svobody sq., 6, Kharkiv, 61022, Ukraine

 
N. A. Vodyanitska, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine

Svobody sq., 6, Kharkiv, 61022, Ukraine

 

References

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) // Eur. Heart J. – 2014. – Vol. 35. – P. 2733–2779.

Maron B. J. Hypertrophic cardiomyopathy / B. J. Maron, M. S. Maron // J. Lancet. – 2012. – Vol.381. – P. 242–255.

Caughey G. E. Multimorbidity research challenges: where to go from here? / G. E. Caughey, E. E. Roughead // J. Comorbidity. – 2011. – Vol. 1. – P. 8–10.

Campbell-Scherer D. Multimorbidity: a challenge for evidence-based medicine. / D. Campbell-Scherer // Evid. Based Med. – 2010. – Vol. 15 (6). – P. 165–166.

Lavie C. J. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss/ C.J. Lavie, R. V. Milani, H. O. Ventura //J. Am Coll Cardiol. – 2009. –- Vol. 53. – P. 1925–1932.

Vuori I. M. Physical activity promotion in the health care system / I. M. Vuori, C. J. Lavie, S. N. Blair // J. Mayo Clin Proc. – 2013. – Vol. 88. – P. 1446–1461.

2013 ESH / ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur. Heart J. – 2013. – Vol. 34. – P. 2159–2219.

2015 AHA/ACC/ASH Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement From the American Heart Association (AHA), American College of Cardiology (ACC), and American Society of Hypertension (ASH) // J. Hypertension. – 2015. – Vol.65. – P.1372–1407.

2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology, American Heart Association. Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons [Text] // J. Circulation. – 2014. – Vol. 130. – P. 1749–1767.

2011 ESC / EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Eur. Heart J. – 2011. – Vol. 32. – P. 1769–1818

2015 ESC / ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) // Eur. Heart J. – 2016. – Vol. 37. – P. 67–119.

2013 ESC / EASD Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) // Eur. Heart J. – 2013. – Vol. 34. – P. 3035–3087.

Kolomoets M. Y. Comorbidity and palmist in therapeutic practice / N. Yu. Kolomoets, A. A. Jasenak // Ukr. med. journal. – 2012. – № 4 (90), VII/VIII. – P. 23–27.

Dawes M. Co-morbidity: we need a guideline for each patient not a guideline for each disease / M. Dawes // Fam. Pract. – 2010. – Vol. 27 (1). – P. 1–2.

Published
2016-11-17
How to Cite
Lakhonina, A. I., Filatova, A. V., Makienko, N. V., & Vodyanitska, N. A. (2016). HYPERTROPHIC CARDIOMYOPATHY IN MULTIMORBIDITY. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine", (31), 48-52. Retrieved from https://periodicals.karazin.ua/medicine/article/view/6358
Section
Clinical case